Belimumab, a BAFF inhibitor approvedfor SLE, may offer CV benefits by improving HDL functionality, as shown in astudy where 6 months of treatment enhanced cholesterol efflux, antioxidantactivity, and paraoxonase-1 levels while reducing oxidized HDL lipids [109].These effects, along with BAFF’s link to subclinical atherosclerosis, suggestpotential vascular protection. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.